Abstract
Several inflammatory mediators regulate the evolution of atherosclerosis. C-reactive protein (CRP) is an acutephase reactant, with a direct effect in inflammatory processes characterizing atherosclerosis. For this reason, CRP is actually considered as a factor, rather than simply a cardiovascular risk marker. The recent demonstration of CRP production not only by the liver, but also within atherosclerotic plaques by activated vascular cells, suggests a possible dual role, as both systemic and tissue molecule. Although more studies are needed, some therapeutic approaches to reduce CRP levels have been performed with encouraging results. Behavioral or pharmacologic interventions have been shown to reduce both CRP levels and the associated risk of cardiovascular acute events. Therefore, although most of national Cardiovascular Associations do not suggest high sensitivity CRP screening of the entire adult population as a public-health measure to stratify the cardiovascular risk, serum hs-CRP levels could be a promising target for therapies focused on reducing cardiovascular risk.
Keywords: cardiovascular risk, statins, C-reactive protein, Atherosclerosis
Current Chemical Biology
Title: Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
Volume: 3 Issue: 1
Author(s): Francois Mach and Fabrizio Montecucco
Affiliation:
Keywords: cardiovascular risk, statins, C-reactive protein, Atherosclerosis
Abstract: Several inflammatory mediators regulate the evolution of atherosclerosis. C-reactive protein (CRP) is an acutephase reactant, with a direct effect in inflammatory processes characterizing atherosclerosis. For this reason, CRP is actually considered as a factor, rather than simply a cardiovascular risk marker. The recent demonstration of CRP production not only by the liver, but also within atherosclerotic plaques by activated vascular cells, suggests a possible dual role, as both systemic and tissue molecule. Although more studies are needed, some therapeutic approaches to reduce CRP levels have been performed with encouraging results. Behavioral or pharmacologic interventions have been shown to reduce both CRP levels and the associated risk of cardiovascular acute events. Therefore, although most of national Cardiovascular Associations do not suggest high sensitivity CRP screening of the entire adult population as a public-health measure to stratify the cardiovascular risk, serum hs-CRP levels could be a promising target for therapies focused on reducing cardiovascular risk.
Export Options
About this article
Cite this article as:
Mach Francois and Montecucco Fabrizio, Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk, Current Chemical Biology 2009; 3 (1) . https://dx.doi.org/10.2174/2212796810903010060
DOI https://dx.doi.org/10.2174/2212796810903010060 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Increasing Neurogenesis with Fluoxetine, Simvastatin and Ascorbic Acid Leads to Functional Recovery in Ischemic Stroke
Recent Patents on Drug Delivery & Formulation Editorial: Ischemic Stroke Prevention
Current Vascular Pharmacology Cardiovascular Disease in the Systemic Vasculitides
Current Vascular Pharmacology Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends
Current Pharmaceutical Design Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry Subject Index to Volume 2
Current Vascular Pharmacology Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era
Current Drug Metabolism Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus
Current Diabetes Reviews